GlassScriptPhysician profile
Keith W Stampher
NPI 1477764413
$4,266.95
in general payments reported to CMS, 2019-2025
32 companies · $42.65 in 2025
The $42.65 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $462 · 2021: $891 · 2022: $902 · 2023: $1,070 · 2024: $667 · 2025: $42.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $766.23 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $595.61 | 2019-2024 | Synjardy, Tradjenta, Jardiance |
| Amgen INC. | $437.84 | 2019-2024 | Otezla, Repatha |
| Abbvie INC. | $436.99 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $316.08 | 2019-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $283.96 | 2019-2024 | Wegovy |
| Esperion Therapeutics, INC. | $182.97 | 2021-2024 | Nexletol |
| Pfizer INC. | $132.80 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $131.59 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $110.97 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $101.27 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $95.11 | 2019-2023 | Seglentis, Livalo |
| Glaxosmithkline, LLC. | $83.91 | 2019-2023 | Shingrix, Arexvy |
| Exact Sciences Corporation | $72.35 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $60.60 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $50.93 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $48.82 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.97 | 2022 | |
| Astellas Pharma US INC | $41.88 | 2023 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $30.41 | 2022-2023 | Belsomra |
| Eisai INC. | $27.79 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.46 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $23.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.06 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.47 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.48 | 2021 | |
| Redhill Biopharma INC. | $16.99 | 2023 | |
| Shire North American Group INC | $16.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.74 | 2020 | |
| Exeltis, USA INC. | $15.97 | 2023 | Slynd |
| Inogen, INC. | $15.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Stampher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.